Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

The Food and Drug Administration has authorized the use of Labcorp's blood-based in-vitro diagnostic test that works by ...

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its ...

Launch and availability of the test demonstrates Labcorp’s commitment to neurology and to improving the health and lives of the millions afflicted by neurodegenerative and related diseases.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based ...

To help facilitate more effective venom therapy, Labcorp, a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support interpretative test report for its ...

Labcorp will begin testing for monkeypox using the CDC's orthopoxvirus, becoming the first national laboratory to do so. The testing will be completed in Labcorp's main lab in North Carolina.

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its ...

BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its ...

Labcorp’s Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy.